Cargando…

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity. Increased circulating vasopressin (AVP) concentrations are supposed to play a role in the progression of ADPKD. We hypothesized that ADPKD patients have a more severely impaired u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zittema, Debbie, Casteleijn, Niek F., Bakker, Stephan J. L., Boesten, Lianne S. M., Duit, A. A. Margreeth, Franssen, Casper F. M., Gaillard, Carlo A. J. M., Gansevoort, Ron T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5231267/ https://www.ncbi.nlm.nih.gov/pubmed/28081165 http://dx.doi.org/10.1371/journal.pone.0169263

Ejemplares similares

The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels
por: Ettema, Esmée M., et al.
Publicado: (2017)

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD
por: Messchendorp, A. Lianne, et al.
Publicado: (2019)

Changes in Plasma Copeptin Levels during Hemodialysis: Are the Physiological Stimuli Active in Hemodialysis Patients?
por: Ettema, Esmée M., et al.
Publicado: (2015)

Arginine Vasopressin and Copeptin in Perinatology
por: Evers, Katrina Suzanne, et al.
Publicado: (2016)

The Presence of Kidney Cyst Infections in Patients With ADPKD After Kidney Transplantation: Need for Urological Analysis?
por: Geertsema, Paul, et al.
Publicado: (2022)

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
por: Messchendorp, A Lianne, et al.
Publicado: (2019)

The Circadian Rhythm of Copeptin, the C-Terminal Portion of Arginine Vasopressin
por: Beglinger, Svetlana, et al.
Publicado: (2017)

Copeptin, a Surrogate Marker for Arginine Vasopressin, Is Associated With Cardiovascular and All-Cause Mortality in Patients With Type 2 Diabetes (ZODIAC-31)
por: Riphagen, Ineke J., et al.
Publicado: (2013)

Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure
por: Ostergaard, Louise, et al.
Publicado: (2014)

THU114 Postsurgical Use Of Copeptin In The Prediction Of Postoperative Arginine Vasopressin Deficiency
por: Erickson, Dana Z, et al.
Publicado: (2023)

Cancer and the Vasopressin Gene: Radioimmunoassay Values and Commentary on Copeptin as a Plasma Marker
por: North, William G
Publicado: (2023)

Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome
por: Karbek, Basak, et al.
Publicado: (2014)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Renal Volume in ADPKD Patient Evaluation
por: Galliani, M., et al.
Publicado: (2020)

The water deprivation test and a potential role for the arginine vasopressin precursor copeptin to differentiate diabetes insipidus from primary polydipsia
por: de Fost, M, et al.
Publicado: (2015)

Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease
por: Kocyigit, Ismail, et al.
Publicado: (2016)

Limited Role of Endogenous Vasopressin/Copeptin in Stimulation of ACTH–Cortisol Secretion during Glucagon Stimulation Test in Humans
por: Malicka, Katarzyna, et al.
Publicado: (2022)

Vasopressin surrogate marker copeptin as a potential novel endocrine biomarker for antidepressant treatment response in major depression: A pilot study
por: Agorastos, A., et al.
Publicado: (2021)

Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
por: Messchendorp, A. Lianne, et al.
Publicado: (2018)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

A Joint Evaluation of Neurohormone Vasopressin-Neurophysin II-Copeptin and Aortic Arch Calcification on Mortality Risks in Hemodialysis Patients
por: Chang, Jia-Feng, et al.
Publicado: (2020)

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression
por: Messchendorp, A. Lianne, et al.
Publicado: (2017)

The BC ADPKD Network: A Comprehensive Provincial Approach to Support Specialized and Locally Delivered Multidisciplinary ADPKD Care
por: Bevilacqua, M., et al.
Publicado: (2021)

The association of urinary epidermal growth factors with ADPKD disease severity and progression
por: Harskamp, Laura R, et al.
Publicado: (2023)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Intrafamilial Variability of ADPKD
por: Lanktree, Matthew B., et al.
Publicado: (2019)

Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study
por: Agorastos, Agorastos, et al.
Publicado: (2020)

MR Brain Screening in ADPKD Patients: To Screen or not to Screen?
por: Capelli, I., et al.
Publicado: (2021)

Exome sequencing of Saudi Arabian patients with ADPKD
por: Al-Muhanna, Fahad A., et al.
Publicado: (2019)

Lower body mass index and mortality in older adults starting dialysis
por: Polinder-Bos, Harmke A., et al.
Publicado: (2018)

Publisher Correction: Lower body mass index and mortality in older adults starting dialysis
por: Polinder-Bos, Harmke A., et al.
Publicado: (2018)

Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study
por: Arjune, Sita, et al.
Publicado: (2023)

Imaging Biomarkers in Young Patients With ADPKD
por: Yang, Xinyi, et al.
Publicado: (2023)

Simultaneous laparoscopic nephrectomy in ADPKD
por: Baishya, Ramen Kumar, et al.
Publicado: (2010)

Polycystins, ADPKD, and Cardiovascular Disease
por: Kuo, Ivana Y., et al.
Publicado: (2019)

Defining Cardiac Dysfunction in ADPKD
por: Kuo, Ivana Y.
Publicado: (2023)

Cardiovascular Manifestations and Management in ADPKD
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Copeptin in anorexia nervosa
por: Goetze, Jens P., et al.
Publicado: (2020)

129 Urine Osmolality (Uosm) Is a Reasonable Marker of Acute (TKV) and Longer-term (eGFR) Efficacy of Vasopressin Receptor Antagonism in ADPKD: Post-hoc Analysis of TEMPO 3:4
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vn2gpmo7iaio1as645hbd1qsm3